Singapore markets closed

Precision BioSciences, Inc. (DTIL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4500-0.0100 (-0.68%)
At close: 04:00PM EDT
1.4400 -0.01 (-0.69%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.4600
Open1.4900
Bid1.4300 x 900
Ask1.4500 x 2900
Day's range1.4350 - 1.5900
52-week range1.1100 - 14.3800
Volume12,954,261
Avg. volume1,859,937
Market cap90.156M
Beta (5Y monthly)1.81
PE ratio (TTM)N/A
EPS (TTM)-0.6700
Earnings date10 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.33
  • Zacks

    Precision BioSciences' (DTIL) Stock Up This Week: Here's Why

    Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.

  • Business Wire

    Precision BioSciences Announces $50 Million Offering of Common Stock

    DURHAM, N.C., June 21, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately $50.0 million. The offering is expected to close on or about June 24, 2022, subject to customary closing conditions. All

  • Business Wire

    Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

    DURHAM, N.C., June 21, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG (the "Agreement"). As part of the Agreement, Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a ther